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INTRODUCTION
1
:  
Risk management is not new – we do it informally all the 
time. Risk management techniques have been in use for 
decades. In 1960s saw the creation of reliability 
engineering approaches (e.g., FEECA and HACCP). ISO -
13485 also was accepted as a risk management standard 
throughout the product life cycle.  
Risk management has been part of the pharmaceutical 
industry for many years. The publication of ICH Q9 
―Quality Risk Management‖ in 2005 is having significant 
impact on pharmaceutical industry. The FDA and other 
regulatory bodies, is embracing the Q9 concepts.  ICH ―Q9 
QRM  is developed by the Expert Working Group 
(Quality) of the International Conference on 
Harmonization of Technical Requirements for Registration 
of Pharmaceuticals for Human Use which describes a 
model for a pharmaceutical quality system by providing 
principles and examples of tools for quality risk 
management and approach to identifying, scientifically 
evaluating and controlling potential risks to quality. In 
general Q9 provides high level guidance regarding 
identification, estimation, evaluation, controlling, 
monitoring and documentation of risk management 
process. The Q9 defines risk as the combination of the 
probability of occurrence of harm and the severity of that 
harm.    
GMP requirements are designed to address risk.  For 
example, the specific GMP requirements for sterile 
products are designed to mitigate the risk of sterility 
failure. From a GMP point of view, we are only concerned 
with risks associated with quality, safety and efficacy – 
QRM where as organisations use risk approaches in other 
areas, e.g. to ensure resources are utilised in the most 
effective way.   
DEFINING RISK 
2
: 
Preliminary working definitions from ICH EWG on QRM 
Q9: 
Risk: Combination of the probability of occurrence of 
harm and the severity of that harm. ISO 14971. 
Harm: Damage to health, including the damage that can 
occur from loss of product efficacy, safety, quality or 
availability.  
Quality: Degree to which a set of inherent characteristics 
of a product, system or process fulfils requirements  
Requirements: Needs or expectations that is stated, 
generally implied or obligatory by the patients or their 
surrogates (e.g. health care professionals, regulators and 
legislators) 
Combining key terms:  Risk to quality is the 
probability/severity that drug will fail to meet the 
needs/expectations of the patients and their surrogates as 
shown in Figure1. 
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WHAT IS QRM
2
? 
"Quality Risk Management is a systematic process for the 
assessment, control, communication and review of risks 
to the quality of the medicinal product across the product 
lifecycle."  (ICH Q9) 
They are called enablers because they constitute a tool or 
process which provides the means to achieve an objective. 
The importance of QRM is such that a whole ICH 
guideline, Q9, has been devoted to it. 
"A Quality Risk Management process organizes 
information to support a risk decision to be made within a 
risk management process. It consists of the identification 
of hazards and the analysis and evaluation of risks 
associated with exposure to those hazards."   (ICH Q9)  
The QRM system should ensure that the evaluation of the 
risk to quality is based on scientific knowledge, experience 
with the process and ultimately links to the protection of 
the patient and the level of effort, formality and 
documentation of the QRM process is commensurate with 
the level of risk. 
Quality risk management system can be applied both 
proactively and retrospectively. 
Principles of QRM
2, 3
: 
The internationally harmonized guideline, ICH Q9 Quality 
Risk Management (4,5), stated overarching principles for 
quality risk management in the pharmaceutical industry: 
1. Risk assessment should be used to assess how to ensure 
compliance and to determine the resulting prioritization for 
action—not for a decision regarding the need to fulfill 
applicable regulations or legal requirements.  
2. Risk can only be effectively managed when it is 
identified, assessed, considered for further mitigation, and 
communicated. This principle embodies the four stages of 
an effective QRM process as defined by ICH Q9: 
-  Risk assessment - Risk control -  Risk communication 
-  Risk review 
3. All the quality risk evaluations must be based on 
scientific and process-specific knowledge and ultimately 
linked primarily to the protection of the patient. Risk 
assessment is based on the strong understanding of the 
underlying science, applicable regulations, and related 
processes involved with the risk under analysis.  
4. Effective risk management requires the potential impact 
of the risk, and ownership of the results of any risk-
management assessment.  
5. Risk assessment must take into account the probability 
of a negative event in combination with the severity of that 
event.  
QRM Covers the Topics such as: 
 Principles of risk management (analysis, control and 
management) 
 Regulatory guidance for applying risk management in 
pharmaceuticals - FDA, EU/PICs/TGA, ICH 
 ICH Q9 - Pharmaceutical Risk Management 
 Risk analysis and risk control applications in design 
control 
 Quality by Design - Risk analysis in design and 
development of products 
 Application of risk analysis and risk to quality 
management systems and CAPA systems 
 Application of risk assessment for managing product 
complaints 
 Application of risk analysis in compliance and 
auditing of pharmaceutical operations 
 Hazard Analysis and Critical Control Point (HACCP) 
in production and process control 
 Application of risk principles in commissioning, 
qualification and process validation 
 Development of a Risk Management Master Plan 
INTEGRATION OF QUALITY RISK 
MANAGEMENT
2, 4
: 
QRM is a process that supports science-based & practical 
decisions when integrated into quality systems such as: (as 
depicted in Figure: 2)  
- Development                      -  Validation                    -  
Quality defects investigations   
- Auditing & Inspection       -  Change Management   -  
Documentation  and  Training 
 
RISK-MaPP: 
Risk-MaPP provides a scientific, risk-based approach 
based on ICH Q9 for setting health-based cross-
contamination and cleaning validation limits. These limits 
drive the risk controls that are implemented on a case-by 
case basis to maintain product quality (as depicted in 
Figure: 3)   
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Risk Factors consist of: Hazards or potential sources of 
harm and consequences or the potential outcomes resulting 
from the hazard. 
Risk Components include: Severity of harm (a measure 
of the degree of harm), Probability of harm (frequency of 
occurrence of the hazard) and Detection of risk (the ability 
to discover or determine the existence of the hazard) 
The FDA Expects the Risk Management to follow a 
basic process of: 
     -  Interpreting a product’s benefits and risks 
     -  Implementing interventions to minimize a product’s 
risks 
     -  Evaluating interventions in light of new knowledge 
that is acquired over time  
     -  Revising interventions when appropriate. 
QRM PROCESS OVERVIEW
1, 5, 6, 7
: 
The QRM program consists of four major components:  
- Risk Assessment 
- Risk Control  
- Risk Communication 
- Risk Review  
All four components are essential (Figure: 4). All the 
QRM methods (as described in Table: 1) should address 
the mentioned four basic components.
 
 
Figure 4: Components of QRM 
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Team selection and method selection are also plays a vital 
role in the risk management process, so care should be 
taken while selection of risk management team and 
method. 
Failure Mode Effects Analysis (FMEA) is the preferable 
method for risk management in the pharmaceutical 
industry as FMEA analysis include higher reliability, 
better quality, increased safety and its contribution towards 
cost saving includes decreased development time and 
reduced waste and non value added operations. 
Initiating QRM process: 
The initiating phase of QRM process involves 
understanding the risk event by defining and agreeing the 
context, the scope and the tolerability criteria for the QRM, 
together with any underlying assumptions. It should 
involve all the stakeholders, all the relevant information is 
assembled and shared. The scope clearly establishes the 
boundaries of the process, system, project or activity being 
assessed.    
QUALITY RISK ASSESSMENT
8, 9, 10
: 
Quality Risk assessment is a systematic process of 
organizing information to support a risk decision to be 
made within a risk management process. It consists of the 
identification of hazards and the analysis and evaluation of 
risks associated with exposure to those hazards."   (ICH 
Q9)  
The assessment process must address the questions such 
as:  
What might go wrong?  
What is probability?  
What are the consequences for product quality? 
What the failure be detected and how?  
The quality risk assessment process also seeks to identify 
opportunities to improve processes. The output from the 
risk assessment must specify a risk owner to ensure the 
documentation and CAPA implementation of the managed 
risk. 
Quality Risk Identification: 
Risk identification shall consist of the use of information 
to identify hazards or potential risks. Information used to 
identify risk includes historical data, theoretical analysis, 
and informed opinions. The risk to be considered includes 
patient safety, product non-conformance, and fitness for 
use, specification and adulteration. 
In this first need to identify the right team of technical 
experts to analyze the risk by meetings & brainstorming 
sessions to capture key information to allow analyzing, 
respond and manage the risk. During this step risk 
identifier, risk description, risk indicator, risk category 
(e.g. Safety, technical, commercial etc ), risk identification 
stage etc shall be captured. 
Quality Risk Analysis: 
During quality risk analysis a detailed understanding of the 
probability that the identified risk will occur shall be 
estimated. It can also include detectability.  
 
Table 2: A simple quality risk analysis tool 
The key activities to be performed during risk analysis 
include to understand the impact of risk, to rank the 
significance of risk (by scoring 1 to 5, where 1 = low & 5 
= high), to calculate the risk score (Risk Score = Severity x 
Probability), colour code the risk based on score (define 
Red, Blue and Green bands e.g. acceptable risk = Green, 
unacceptable risk = Blue, Intolerable = Red). 
Quality Risk Evaluation: 
Quality risk evaluation includes comparison of identified 
and analysed risk against pre-defined acceptance criteria 
and consideration of probability, severity and detectability. 
The complete risk assessment shall result in an overall risk 
value expressed as either   
 A qualitative description of a range of risk using 
descriptions such as high, medium or low. 
 A quantitative description of risk expressed 
numerically on probability scale of 0 to 100 percent.  
Detectability: Likelihood that the fault will be noted 
before harm occurs. 
 High – when the control is likely to detect the 
negative event or its effects 
 Medium – when the control may detect the 
negative event or its effects 
 Low – when the control is not likely to detect the 
negative event or its effects 
 Zero –when no detection control in place 
Quality Risk Definitions: 
Intolerable (marked in RED): Work to eliminate the 
negative event or introduce detection controls is required 
as a priority. 
Unacceptable (marked in BLUE): Work to reduce the 
risk or control the risk to an acceptable level is required. 
Acceptable (marked in GREEN): The risk is acceptable 
and no risk reduction or detection controls are required.  
Where,  
Severity: Is the impact on patient safety, product quality 
and data integrity. 
Probability: Is the likelihood of the fault occurring. 
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Quality Risk Evaluation Tools: 
There are many tools which can be used to identify and assess the risks from hazards.  It’s necessary to use multiple tools / 
techniques to meet all the requirements.  
 
 
Table 2: A Simple Quality Risk Evaluation Tool 
QUALITY RISK CONTROL: 
This activity depending on the trend and importance and 
may require an improved effort by the technical team to 
make sure that identified risks are dealt with fittingly. 
Quality risk control describes"Actions implementing risk 
management decisions" which include risk reduction (if 
applicable) and risk acceptance.  Risk control must 
address the questions such as     is the risk acceptable 
without further action? & what can be done to reduce, 
control or eliminate risks?  
Actions implementing risk management decisions” 
(ICH Q9) includes risk reduction & risk acceptance. 
Quality Risk Reduction:  
Quality risk reduction focuses for avoidance of quality 
risk when the risk exceeds an acceptable level. Risk 
reduction includes: 
 Actions taken to lessen the probability of occurrence 
of harm.   
 Actions taken to lessen the probability of occurrence 
of the severity of that harm. 
 Usually CAPA and CHANGE CONTROL. Therefore, 
the risk assessment must be repeated to identify and 
evaluate any possible change in the risk profile. 
Quality Risk Acceptance: 
Quality risk acceptance is the decision to accept risk. If 
risk reduction action taken, follows re-analysis and 
evaluation. On case to case basis QRM strategy is 
designed to reduce to an acceptable level depend upon 
many parameters. The documented results of the QRM 
process shall be communicated to the relevant 
stakeholders. 
QUALITY RISK REVIEW: 
Review or monitoring of output/results of the risk 
management process considering new knowledge and 
experience about the risk (ICH Q9) ensures that nothing 
has changed to affect the QRM assumptions, output and 
conclusions and/or to be consider during product review. 
UNCERTAINITY, VARIABILITY AND 
PREDICTABILITY: 
No discussion of risk management is complete without 
mentioning uncertainty and closely related terms, 
variability and predictability. In fact, risk management is 
sometimes referred to as decision making under 
uncertainty. The process of making decisions about the 
future chance of loss – risk - as a projection necessarily 
lacks information about what will really occur in the 
future. This lack of information about the future and even 
about how to appropriately model future events inherently 
involves uncertainty. A complementary concept to 
uncertainty is that of predictability. Predictability is a 
Lotlikar et al                                Journal of Drug Delivery & Therapeutics; 2013, 3(2), 149-154   154 
© 2011, JDDT. All Rights Reserved                                                      ISSN: 2250-1177                                                     CODEN (USA): JDDTAO 
concept occurring in fields as diverse as economics, 
analytical chemistry, and health risk analysis. 
QUALITY RISK MANAGEMENT METHODS
11, 12
: 
A key early step in the execution of a risk analysis is to 
determine the appropriate risk-assessment methods or 
tools. There is no single best choice for any given 
assessment process, and the selection of the appropriate 
risk methodology should be based on the depth of 
analysis required, complexity of the subject risk of 
concern, and the familiarity with the assessment tool. The 
list of generally well-recognized risk-management tools 
shall be:  
 Basic risk management facilitation methods 
(flowcharts, check sheets etc.)  
 Failure Mode Effects Analysis (FMEA)  
 Failure Mode, Effects and Criticality Analysis 
(FMECA)  
 Fault Tree Analysis (FTA)  
 Hazard Analysis and Critical Control Points 
(HACCP)  
 Hazard Operability Analysis (HAZOP)  
 Preliminary Hazard Analysis (PHA)  
 Risk ranking and filtering  
 Supporting statistical tools 
POTENTIAL AREAS FOR RISK MANAGEMENT 
APPLICATION: 
Following are the potential areas identified in the 
pharmaceutical industry for QRM application. 
 Documentation [SOPs, Batch records etc.] 
 Training [Schedules and effectiveness] 
 Quality defects [Complaints, deviations, OOS etc.] 
 Audits [Compliance] 
 Periodic reviews [Revalidation assessment] 
 Change controls [Impact assessment] 
 Development reports [Process and controls 
verification] 
 Facilities, Equipment and Utilities [Components, 
maintenance etc.] 
 Material management [Receipt, storage and 
distribution] 
 Packaging and labeling [Container closure system 
and labeling] 
CONCLUSION: 
The link between risk and reward has never been more 
important than it is now in the pharmaceuticals industry 
as the many established processes and protocols around 
risk management have focused on detecting compliance 
failures or breaches of laws and regulations. 
“If we do not take change by the hand it will surely take 
us by the throat.” 
- Winston Churchill 
The principle goal of risk management at the highest 
organizational levels is to use risk management to bring 
formality to risk-informed decision making which was 
easily associated with resource allocation and ensuring 
patient safety. The key is to apply the appropriate level of 
analytical sophistication for a given level of complexity. 
Ultimately, applying risk management to pharmaceutical 
industry should reduce the number of threats or minimize 
their impact through the consistent use of the 
tools/methods and periodic review. The output of the risk 
management supports to the organization to meets the 
defined goals towards protection of public health. 
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